Vaccine Info

Rabivax-S Rabies Vaccine

Last Reviewed
February 16, 2021

Rabivax-S Rabies Vaccine Description

Rabivax-S has been developed on Vero ATCC CCL81 cells using Pitman Moore (PM3218) strain. It is an inactivated vaccine that is freeze-dried until ready for immunization.

Rabivax-S Rabies Vaccine Indication

RABIVAX-S is indicated for the prevention of rabies in children and adults. It can be used before or after exposure, as a primary immunization, or as a booster dose.

Rabivax is administered intramuscular and/or intra-dermal.

Rabivax-S Rabies Vaccine News

October 20, 2020 - An Overview of Current Uses and Future Opportunities for Computer-Assisted Design of Vaccines for Neglected Tropical Diseases

Rabies vaccines like RabAvert, Rabipur, or Rabivax efficiently induce long-lasting immunity triggering the production of neutralizing antibodies but several doses are required. Regrettably, rabies vaccination is not included in the vaccines covered by the Expanded Programme on Immunization, and they are expensive and not affordable in developing countries.

Rabivax-S Rabies Vaccine Clinical Trials

Clinical Trial NCT03741270: Safety of Rabivax-S for Pre-exposure Prophylaxis

People who are at frequent or continuous risk of exposure to rabies virus should be vaccinated against the disease (pre-exposure prophylaxis). This includes people who work with rabies virus in research or diagnostic laboratories or vaccine production facilities, veterinarians, staff, animal-control and wildlife workers in areas where rabies is endemic. Veterinary students in clinical placements and externships are included in this category. Currently, DVM students at Ross University School of Veterinary Medicine (RUSVM) are vaccinated against rabies in their 7th semester (final pre-clinical semester). Vaccinations are done by RUSVM Health Services using Rabivax-S, produced by the Serum Institute of India (study co-sponsors).

Previously-unvaccinated students receive three injections of vaccine, on day 0, 7 and 21-28. The aim of the study is to generate additional data on safety and tolerability of Rabivax-S administered as pre-exposure prophylaxis to this population.